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Abstract. We have investigated the sorting and pro-
cessing of the amphibian precursor prepro-dermorphin
in mammalian cells. Dermorphin, a D-alanine-con-
taining peptide with potent opioid activity, has been
isolated from the skin of the frog Phyllomedusa sau-
vagei . The maturation of this peptide from the precur-
sor involves several posttranslational steps. Recom-
binant vaccinia viruses were used to infect AtT20,
PC12, and HeLa cells to study the sorting and pro-
cessing of prepro-dermorphin. While this precursor
was not processed in any of the examined cell lines,
AtT20 cells were able to process -40% of a chimeric
T is well established that secretion of peptides and pro-
teins from cells can be either regulated or constitutive
(1). In the former case, products are stored at high con
centration in specialized vesicles which accumulate in the
cytoplasm until exocytosis is triggered by external stimuli.
Conversely, in the constitutive pathway newly synthesized
secretory products are transported to the plasma membrane
and released independent of extracellular signals. While the
constitutive pathway is present in all cells, the regulated
secretion pathway is restricted to certain secretory cells. In
such cells, special sorting mechanisms must exist which di-
rect a set of secretory products to this alternative route. The
precursors of secretory peptides are frequently directed to
the regulated pathway where processing to the mature prod-
ucts takes place. This sorting into the regulated pathway also
functions with heterologous precursors. It has been demon-
strated that in mouse pituitary AtT20 cells transfected with
cDNAs encoding mammalian prohormones the precursors
are stored in secretory vesicles and proteolytically converted
to mature hormones (2, 4, 8, 16, 19, 26, 30). On the other
hand, cells lacking the regulated secretory pathway like
fibroblasts secrete intact prohormones.
In this paper we describe similar experiments using the
cDNA coding for a precursor of peptides present in the skin
of Phyllomedusa sauvagei, a South American tree frog (23).
The end products liberated from this precursor, the hep-
tapeptides dermorphin and deltorphin, have high affinity and
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precursor consisting of the first 241 amino acids of
prepro-enkephalin fused to a carboxy-terminal part of
pro-dermorphin. By immunogold-EM, we could show
that the chimeric protein, but not pro-dermorphin, was
sorted to dense-core secretion granules. The process-
ing products could be released upon stimulation by
8-Br-cAMP. We conclude that the pro-enkephalin part
of the fusion protein contains the information for tar-
geting to the regulated pathway of secretion, while this
sorting information is missing in pro-dermorphin. This
indicates that sorting mechanisms may differ between
amphibian and mammalian cells.
selectivity for p- and 6-opiate receptors, respectively (15,
17) . This biological activity is dependent on the presence of
D-alanine or D-methionine in the second position. By cDNA
cloning, it has been shown that normal codons for these
amino acids are present at the relevant positions, suggesting
the existence of a posttranslational epimerization of the
configuration of certain residues (23, 24) .
From the sequence of these cloned cDNAs, it is evident
that the processing of the precursors for dermorphins and
deltorphins must be rather complex (see Fig. 1 A). Besides
cleavage at pairs of basic amino acids, three additional reac-
tions must take place. These are cleavage of the carboxy-
terminal Glu-Ala dipeptide, formation of the terminal amide,
and epimerization of the second amino acid of the end prod-
uct from the L- to the D-isomer. The temporal orderof these
processing reactions is unknown.
The precursors of skin peptides also have to be sorted to
specialized granules where processingtakes place (5, 7) . One
might assume that sorting of skin peptides occurs by a mech-
anism similar to the regulated pathway of secretion. To an-
swer the question whether these amphibian precursors would
also be sorted and processed in mammalian cells, we have
expressed the cDNA for one of the dermorphin precursors
in mammalian cells. Our results show that in these cells, the
major part of prodermorphin accumulates intracellularly
and is degraded whilethe rest is secreted constitutively with-
out any detectable processing. Conversely, a hybrid proen-kephalin-prodermorphin precursor is sorted into the regu-
lated pathway of secretion and partly processed.
Materials and Methods
PlasmidConstructions
Standard recombinant DNA procedures were used for the construction of
the following plasmids.
p7.51C131-derm. The 663-bp fragment of clone D-1/2 (23) was inserted
into the Smal site of the vaccinia virus expression vector p7.5K-131 after
the tandem early/late 7.5 K promoter. The vector p7.5K-131 contains the
7.5 K promoter of the virus fused to the polylinker of pEMBL-131, which
was ligated between the ClaI and EcoRI sites within the viral thymidine ki-
nase gene and inserted into the plasmid pUC8.
P75K131-enk-derm. The 825-bp BanII-HinfI fragment of the plasmid
pRPE2 (36), which contains the rat prepro-enkephalin cDNA, was treated
by Klenow-Polymerase to fill up the Hinfl site. The 700-bp BamHI-EcoRI
fragment ofp7.5K-131-derm was partially digested by AIuI. This yielded a
262-bp AluI-EcoRI fragment which contains the carboxy-terminal part of
the prodermorphin cDNA. This was ligated to the 825-bp fragment encod-
ing the amino-terminal part ofprepro-enkephalin. After Sl-Nuclease treat-
ment it was inserted intothe Smal siteofthe vector p7.5K-131 after the 7.5 K
promoter.
All vector constructions were confirmed by restriction endonuclease
mapping and in case ofp7.5K-131-enk-derm also by nucleotide sequencing.
CellLinesandCultureConditions
HeLa cells, RK-13 (rabbit kidney) cells, and human 143 TK-cells were
grown in MEM, containing 10% FCS. AtT20 cells were grown in DME
supplemented with 0.35% glucose and 10% heat-inactivated FCS; PC12
cells in DME, containing 10% horse serum and 5% FCS.
Preparation ofRecombinant Vaccinia Viruses
Recombinant vaccinia viruses (vv)l were prepared using the temperature-
sensitive mutant ts7 (6) essentially according to the procedure of Kieny et
al. (14) . Stocks for vv:7.5K-derm and vv.7.5K-enk-derm were prepared by
infecting RK-13 cells. After 2 d at 37°C, cells and medium were harvested
and centrifuged (30 min, 18,000 rpm, 4°C). The pellet was washed in PBS,
centrifugedagain, and then suspended in 1 mM Tris-HCI, pH 9.0, and soni-
cated. The nuclei were removed by centrifugation (2,000 rpm, 5 min). The
virus was collected from the supernatant by centrifugation at 15,000 rpm
through a 36% sucrose cushion for 60 min. The pelleted virus was
resuspended in PBS, homogenized briefly, and stored at -20°C.
Infection ofCells with Vaccinia Virus
Before infection, the virus was sonicated for 30 s, diluted in 250 IL1 PBS
(for a 33-mm dish); cells were washed in PBS and virus was added. The
inoculum was removed after incubation for 1 h at room temperature and
replaced with medium. Polypeptides synthesized in cells infected with the
different recombinant viruses were analyzed by pulse labeling, immunopre-
cipitation, and Western blots.
Production ofAntibodies
All peptides were obtained from Neo Systems (Strasbourg). [L-Ala-
2]dermorphin-Gly-Glu-Ala (decapeptide) was coupled to BSA using
glutaraldehyde (3). [L-Ala-2]dermorphin and dermorphin were coupled to
BSA via the SH group of a cysteine residue introduced at the carboxy ter-
mini of the deamidated peptides, using maleimidobenzoyl-N-succinintide
ester as crosslinker agent (3). Antisera against the peptides were raised in
rabbits (female, NewZealand) . After initial subcutaneous injections at mul-
tiple sites of 100 kg ofthe peptide-protein complex emulsified in complete
Freund's adjuvant, animals were twice boosted at 4-wk intervals using
equivalent amounts ofcomplexes in incomplete Freund's adjuvant. Animals
were bled 15 d after the last injection. Antisera against dermorphin (63 III
1. Abbreviations used in thispaper: VV, vaccinia virus; m.o.i, multiplicity
of infection.
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B), [L-Ala-2]dermorphin (3A), and [L-Ala-21decapeptide (58 IV a) were
obtained.
Radioimmunoassays
Decapeptide RIA: The tracerwas prepared by iodination ofthe decapeptide
with iodine-125 in the presence of chloramineT (12). The monoiodinated
compound was purified by HPLC. The RIA was performed exactly as de-
scribed previously for met-enkephalin (22) with a final dilution of the
decapeptide-antiserum (58 IVa) of 1/240,000. Under these conditions the
sensitivity of the assay (corresponding to a representative value which can
be distinguished from maximum binding with 95% confidence) was 4 fmol
decapeptide/tube with an IC 50 of 40 fmol decapeptide/tube. The cross-
reactivity ofdecapeptide-Lys-Lys and decapeptide-Lys, expressed on a mo-
lar basis, was <0.01%, while that for [D-Ala-2]-decapeptide was 100%.
The RIA for met-enkephalin, performed as described before (22), had
a sensitivity of 1 fmol and an IC 50 of 12 fmol .
Pulse-ChaseExperiments
Confluentcells (33-mmdishes) were infected with the recombinant vaccinia
viruses as before. After incubation for 6 h at 37°C, the cells were washed
with PBS and incubated in methionine-free MEM (Gibco) which was
replaced after 1 hour by fresh medium containing 50 1Ci of L-[31S]-
methionine (Amersham). After labeling for 30 min, cells were washed
twice with medium, containing a tenfold excess of methionine (chase
medium) and incubated for the indicated periods at 37°C in this medium.
Finally, media were collected and after addition of 1 mM PMSF they were
stored at -20°C. The cells were washed twice in ice-cold PBS, harvested
in RIPA-buffer (10 mM Tris.HCl pH 7.6, 150 mM NaCI, 0.1% SDS, 1%
NaDOC, 1% Triton-X-100, 1 mM PMSF) and lysed by vortexing. Cell ex-
tracts were centrifuged (15,000 rpm, 15 min, 4°C) and the supernatants
were storedat -20°C. Forthe experiment with leupeptin, the inhibitor (100
,ug/ml) was added tothe mediumone hour beforetheradioactiveamino acid
was added.
ImmunoprecipitationofPro-dermorphin and
Pro-enkephalin-dermorphin andWesternBlots
Immunoprecipitation with anti-[LAla-2]dermorphin antibody 3A at a dilu-
tion of 1:200 was performed in RIPA buffer. After incubation overnight at
4°C, Protein-A-Sepharose beads (Pharmacia Fine Chemicals, Piscataway,
NJ) washed in RIPA buffer were added. The incubation was continued for
an additional hour, and beads were pelleted and consecutively washedthree
times with RIPA buffer and one time with 50 mM Tris-HCI, pH 7.5. The
beads were taken upinto SDS samplebuffer, boiled for 10 min, centrifuged,
and the supernatants analyzed by SDS-PAGE on 15% gels followed by
fluorography.
For the immunoblots, aliquots of cell extracts and media were fraction-
ated by SDS-PAGE, and transferred to nitrocellulose. This was then in-
cubated with the anti-[L-Ala-2]dermorphin antiserum 3A in a dilution of
1:500 and detected by an anti-rabbit alkaline phosphatase-linked antibody
(BRL).
HPLCAnalysis ofPeptides
Cells were infected with recombinant vv as before. After 16 h at 37°C, the
cells were washed twice with PBS, harvested in 5N acetic acid, 1 mM
PMSF, and lysed by freezing/thawing and brief sonication on ice. Cell de-
bris was removed by centrifugation at 15,000 rpm, the supernatant was
lyophilized, dissolved in 0.1% trifluoroacetic acid (TFA) and applied to a
C8 column (2 x 220 mm, Brownlee) for HPLC. Peptides were separated by
an initial 10-min isocratic elution in 0.1% TFA containing 7% acetonitrile,
followed by 55 min ofa linear gradient of 7-45% acetonitrile in 0.1 % TEN,
at a flow rate of 200 /A/min. 1-min fractions were collected, lyophilized,
and analyzed by RIAs for the decapeptide, [L-Ala-2]dermorphin, dermor-
phin and met-enkephalin.
Peptides secreted from AtT20 cells were analyzed as follows. Confluent
cells were infected with recombinant vv at an m.o.i. of 1. After an incuba-
tion for 16 h the cells were washed twice with serum-free DME, containing
0.07 % BSA, and incubated for 1 h in the same medium, either inthe absence
or in the presence of 5 mM 8-Br-CAMP Media were collected, and 1 mM
PMSF was added and lyophilized. An aliquot was directly assayed by RIA,
the restwas applied to a C8 column, and the fractions wereassayed by RIAs
as described above.
1126Digestion with Trypsin andCarboxypeptidase B
Cells were harvested in 5 N acetic acid and lysed as described above. Cell
debris was removed by centrifugation. The supernatantwas lyophilized, dis-
solved in 50 mM Tris-HCI, pH 8.4, 2 mM Ca-chloride, boiled for 10 min
and incubated with trypsin (50 pg/ml) for 2 h at 37°C. After boiling for 10
min, carboxypeptidase-B (0.1 ;4g/ml) was addedand the incubation was con-
tinued for an additional hour.
Immunogold-electronmicroscopy
AtT20 cells were infected with vv:wt, vv:7.5K-derm or vv:7.5K-enk-derm
at an m.o.i. of 1 for 16 h. The cells were removed from the monolayer with
20 jAg/ml of proteinase K on ice, fixed in 8% para-formaldehyde (in 200
mM Hepes, pH 7.4), cryo-sectioned, and labeled with antibodies against
[L-ala-2]-dermorphin (3A) asdescribed by Griffiths et al. (11). Forquantita-
tion, random micrographs were taken at a primary magnification of28,000
of the granules, irrespective of labeling. The number of gold particles per
area of granule profile was estimated by point counting as described (10).
Results
Expression ofthe Prepro-dermorphincDNA
inMammalian Cells
We decided to use recombinant vaccinia virus (vv) for the
expression of prepro-dermorphin in animal cells. This virus
system has the advantage that the foreign protein is expressed
in high yields and that many different cell lines can be in-
fected. The cDNA was inserted after the 7.5 K promoter into
the vaccinia virus vector 7.5K-131 and recombinant vaccinia
virus (vv:7.5K-derm) was prepared.
In a first set of experiments three different cell lines were
infected with recombinant vaccinia virus. These were HeLa
cells which only secrete proteins via the constitutive path-
way, as well as AtT20 and PC12 cells, two neuroendocrine
A
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cell lines where regulated and constitutive pathways coexist.
Confluent cells were infected with vv :7.5K-derm for 16 h,
then labeled for 1 h with L-['H]tyrosine and subsequently
incubated for 2 h in the presence of unlabeled tyrosine. Ex-
tracts from cells and media were boiled and then analyzed
by SDS-PAGE. Pro-dermorphin with an Mof 29 kD could
be detected in cells as well as in media (data not shown) . It
was shown previously that in vitro translation of prepro-der-
morphin cDNA yielded a polypeptide with anMof 31 kD.
This was cleaved to pro-dermorphin (M 29 kD) in the
presence of dog pancreas microsomes (our unpublished ex-
periments) .
For further characterization of the dermorphin precursor,
cell extracts and media were digested with trypsin and car-
boxypeptidase B to liberate the processing intermediate
[L-Ala-2]dermorphin-Gly-Glu-Ala, henceforth called the
decapeptide. After immunoprecipitation, the radioactive
decapeptide was identified by HPLC. The product comi-
grated with the [L-Ala-2]decapeptide, while no label could
be detected in the [D-Ala-2]decapeptide region (data not
shown).
To analyze the secretion kinetics of pro-dermorphin in
HeLa and AtT20 cells, these were infected for 6 h with
recombinant vaccinia virus. Cells were then labeled for 30
min with L-[35S]-methionine and subsequently incubated in
thepresence ofexcess unlabeled methionine for the indicated
periods of time. Extracts from cells and media were immu-
noprecipitated and then analyzed by SDS-PAGE . In HeLa as
well as in AtT20 cells (see Fig. 2, A and B), less than one
third ofprodermorphin is secreted during a 4-h chaseperiod,
while the rest is retained in the cells and degraded slowly.
This degradation is retarded in the presence of leupeptin (see
Fig. 2 C), an inhibitor of lysosomal proteases.
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Figure 1. Schematic represen-
tation of prepro-dermorphin
and the chimeric precursor pre-
pro-enkephalin-dermorphin.
InA, thepostulatedprocessing
of pro-dermorphin is shown.
The following reactions must
take place to liberate dermor-
phin from its precursor: (1)
cleavage at and removalofpairs
of basic amino acids; (2) re-
moval ofthe carboxy-terminal
Glu-Ala dipeptide; (3) forma-
tion of the carboxy-terminal
amide; and (4) epimerization
of the alanine from the L- to
the D-isomer. B presents the
fusion protein consisting of
amino acids 1-241 of rat pre-
proenkephalin and residues
124-197ofprepro-dermorphin.
DM, dermorphin; DL, deltor-
phin; M, met-enkephalin; O,
octapeptide; L, leu-enkephalin.To determine the extent of processing of pro-dermorphin
in the various cell lines, we usedRIAs . Polyclonal antibodies
were prepared against dermorphin, [L-Ala-2]dermorphin,
and the decapeptide . Confluent cells (HeLa, PC12 and AtT
20) were infected for 16 h with recombinant vaccinia virus,
media were collected, and cells were subsequently lysed
by treatment with 5 N acetic acid . Aliquots of cell extracts
and media werethen analyzed by RIAs . Neither the decapep-
tide nor smaller products could be detected in significant
amounts, indicating that prodermorphin is not processed in
any of these cells . In the case of HeLa cells this was to be
expected as these do not have a regulated pathway of secre-
tion . Moreover, for PC12 cells, which have a regulated path-
way of secretion, it has been reported that these cells are not
able to process foreign hormone-precursors (26) . However,
the fact that themouse anterior pituitary cell lineAtT20 did
not process this amphibian precursor was quite unexpected .
In AtT20 cells transfected with the cDNA of human pro-
insulin, the precursor is directed to the regulated pathway
and processed to insulin (19) . Similar results have been ob-
tained for othermammalian hormone precursors (2, 4, 8, 16,
26, 30) .
The fact that this amphibian precursor is not processed in
AtT20 cells could be due to the following reasons . (a) Pro-
dermorphin is not recognized by the endoprotease(s) in-
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volved in processing at the pairs of basic amino acids ; and
(b) in these cells, the precursor was not directed to the regu-
lated pathway of secretion and thus did not reach the com-
partment where the processing enzymes are active .
Expression of the Prepro-enkephalin-dermorphin
cDNA inMammalian Cells
To discern between these alternatives, a chimeric precursor
was constructed which contains the amino-terminal 241
amino acids ofprepro-enkephalin and a carboxy-terminal re-
gion derived from pro-dermorphin (Fig . 1 B) . It has earlier
been shown (30) that pro-enkephalin, expressed by recom-
binant vaccinia virus in AtT20 cells, is cleaved to met-
enkephalin .
The prepro-enkephalin-dermorphin cDNA was inserted
after the 7.5 K promoter of vv and recombinant virus was
prepared (vv.7.5K-enk-derm) . AtT20 cells were then in-
fected with this virus for 16 h . Cell extracts were analyzed
by SDS-PAGE and Western blotting. As shown in Fig . 3, two
fusion proteins are present (Fig . 3, lane 4), of which the
larger is N-glycosylated in the pro-enkephalin part (31, 35) .
This is indicated by the fact that in the presence of tunicamy-
cin, this larger product is absent (data not shown) . AtT20
cells infected with this recombinant virus were also analyzed
by HPLC and RIAs for the presence of met-enkephalin,
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Figure 2. Pulse-chase experi-
ments . HeLa (A) and AtT20
cells (B) were infected with
vv.7.5K-derm for 6 h, labeled
for 30 min with L-['SS]methi-
onine and chased for the times
indicated . Cells and medium
were treated with anti-[L-Ala-
2]-dermorphin antiserum 3A
and immune complexes were
resolvedby SDS-PAGE on 15
gels . (C) Same experiment as
in A, but in the presence of
100 ug/ml of leupeptin . The
amountofradioactive pro-der-
morphinpresent afterthepulse
(30P) is set at 100% and frac-
tions thereof present in cells
and medium after the chase
periods are given below each
figure . Arrows indicate the po-
sition of pro-dermorphin mi-
grating with anM of 29 kD.decapeptide, dermorphin, and [L-Ala-2]dermorphin . The
results obtained with cell extracts are shown in Fig . 4 and
Table I .
In Table I, the amount of decapeptide and met-enkephalin
present after and before digestion with trypsin and carboxy-
peptidase B are compared . These values correspond to the
total amount of precursor and the extent of processing,
respectively. In case of the fusion protein, >40% of the im-
munoreactivity present in the cell extract is already in the
decapeptide form before digestion . The corresponding value
for prodermorphin was only 5%, which corroborates the
above mentioned findings that this amphibian precursor is
not processed to any significant extent in AtT20 cells . Im-
munoreactive material was identified as decapeptide and
met-enkephalin by HPLC (see Fig . 4) .
These results demonstrate that the processing enzymes of
AtT20 cells can liberate the decapeptide from prodermor-
phin . On the other hand, using the respective antibodies, no
evidence for the presence of [L-Ala-2]dermorphin or der-
20 30 40
retention time (min)
Figure3 Immunoblotting . AtT
20 cells were either mock in-
fected (lane 1) or infected with
wt virus (lane2), vv :7.5K-derm
(lane 3) or vv .7.5Kenk-derm
(lane 4) for 16 h. Cell extracts
were fractionated by SDS-
PAGE, transferred to nitro-
cellulose, incubated with the
anti-[L-Ala-21-dermorphin an-
tiserum 3A, and then treated
with an antirabbit alkaline
phosphatase-linked antibody
(BRL) . The fusion protein
(lane 4) is partly N-glycosyl-
ated . The minor prodermor-
phin polypeptides with higher
molecular weights (lane 3)
probably represent O-glyco-
sylated forms .
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Table L Processing ofPro-enkephalin-dermorphin
and Pro-dermorphin
vv:7.5K-enk-derm
vv:7.5K-derm
AtT-20 cells were infected with vv :7.5K-derm or vv :7.5K-enk-derm at an
m.o .i . of 5 for 16 h . Cells were extracted by 5 N acetic acid, lyophilized to
dryness, and analyzed by RIAs for decapeptide and met-enkephalin either be-
fore (-) or after (+) digestion with trypsin and carboxypeptidase B. Each
value is themean of three independent experiments . On serial dilutions the im-
munoreactive material gave a curve parallel to the standards . The identity of
the immunoreactive material was further identified by HPLC (see Fig . 4) . The
percentage of processing is given in brackets .
morphin could be obtained (data not shown) . This indicates
that in AtT20 cells further processing of the decapeptide,
i.e ., removal of the carboxy-terminal Glu-Ala dipeptide and
conversion of the L- to the D-alanine, does not take place .
As controls, HeLa cells and PC12 cells were also infected
with the same recombinant vaccinia virus . In these cells, no
evidence for the processing of the pro-enkephalin-dermor-
phin fusion protein could be obtained (data not shown) .
The above experiments indicate that in AtT20 cells the
proenkephalin-prodermorphin fusion protein, but not pro-
dermorphin itself, can enter the regulated pathway of secre-
tion . It is known that processing in this pathway mainly takes
place after acidification of immature secretory vesicles (20,
21) . That this route is also taken by the chimeric precursor is
supported by the fact that its processing is abolished in cells
treated with 10mM ammonium chloride (data not shown) .
Regulated Secretion ofthe Processing Products
The previous experiments indicate that the hybrid precursor
is processed in AtT20 cells with high efficiency. We also
Figure 4. HPLC analysis of
cell extracts followed by RIAs.
AtT20 cells were infected with
vv-7.5K-derm (o---O) or vv :
7.5K-enk-derm (m--E) at an
m.o .i . of 5 for 16 h . Cells
were extracted with 5 N acetic
acid, lyophilized, dissolved in
0.1% TFA, and applied to a
C8 HPLC column for reversed
phase chromatography. Frac-
tions were collected and ana-
lyzed by RIAs for decapeptide
(A) and met-enkephalin (B) .
20
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The arrows indicate the elu-
tion times of the standard pep-
retention time (min)
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tides.
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Decapeptide
fmol HR/106
Try/CPB
cells
Met-
fmol IR/106
Try/CPB
nkephalin
cells
9,072 3,920 44,640 11,780
(43%) (26%)
24,500 1,240
(S%)wanted to check whether the processing products could be
released from their site of storage by secretagogues . Cells
were infected with recombinant vaccinia virus for 16 h . Sub-
sequently, 8-bromo-cAMP was added and the amount of
peptides released after 1 h was measured . As shown in Fig .
5, in the presence of 8-bromo-cAMP the amount of met-
enkephalin and decapeptide in themedium increased five- to
sixfold . This confirms that in AtT20 cells, the proenkeph-
alin-prodermorphin fusion protein enters the regulated path-
way of secretion and that the processing products are stored
and released upon suitable stimulation .
Pulse-ChaseExperiments
The different fate of prodermorphin as opposed to the pro-
enkephalin-prodermorphin hybrid protein was investigated
further by pulse-chase experiments . AtT20 cells were in-
fected with vv:7.5K-enk-derm for 6 h, pulse-labeled with
L-["S]methionine for 30 min and then incubated in the pres-
ence of excess unlabeled methionine for different periods of
time . As shown in Fig . 6, the fusion protein and its N-gly-
cosylated form are processed rather quickly in AtT20 cells .
In contrast, HeLa cells constitutively secrete the chimeric
precursor in the unprocessed form (data not shown) . As
shown earlier, pro-dermorphin turns overmuch more slowly
during the chase period (see Fig . 2, A and B) .
Pro-enkephalin-dermorphin, butNotPro-dermorphin
Is Sorted to Dense-core Secretion Granules
The above results clearly indicate that prodermorphin and
the proenkephalin-prodermorphin hybrid protein enter dif-
ferent subcellular compartments . To investigate this further,
we employed immunogold-EM using a polyclonal peptide-
antibody against [LAla-2]dermorphin on thawed cryo-
sections . This antibody also recognizes prodermorphin as
well as the pro-enkephalin-prodermorphin fusion protein
(see Fig. 3) . Using this technique the proenkephalin-
prodermorphin fusion protein could be detected in signifi-
cant amounts in dense-core secretion granules (see Fig . 7) .
Conversely, no significant labeling of these granules could
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Figure 6 . Pulse-chase experiment with the prepro-enkephalin-
dermorphin fusion protein . AtT20 cells were infected with vv :
7.5K-enk-derm for 6 h, pulse labeled for 30 min with L-['SS]me-
thionine and chased for the times indicated . Cells and media were
treated with anti-L-dermorphin antiserum 3A, and immune com-
plexes were resolved by SDS-PAGE on 15 % gels . Arrows indicate
glycosylated pro-enkephalin-dermorphin (M r 38 kD) and unglyco-
sylated pro-enkephalin-dermorphin (M r 36 kD) .
be detected in AtT20 cells producing prodermorphin . A
quantitation of these results is shown in Table II .
Discussion
The present work addresses two questions, namely whether
sorting and processing mechanisms were conserved during
the evolution of animal organisms . Sorting into the regulated
pathway of secretion is present in specialized animal cells (1) .
The process has only been studied in some detail in mam-
malian endocrine cells, and current evidence indicates that
it is neither cell nor species specific . After transfection ofthe
cDNAs for several mammalian prohormones into different
neuroendocrine cells mature hormones were generated,
stored, and released upon addition of secretagogues (2, 4,
8, 16, 19, 26, 28, 30) . The molecular mechanism involved
in directing certain molecules to the regulated pathway of
secretion is currently not known . As no conserved sequences
are present, e.g ., among the different peptide precursors,
other factors must be involved . The condensation-sorting hy-
pothesis proposes that aggregation ofcertain secretory prod-
20 30 40
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Figure 5 . Regulated secretion
°'
￿
of the processing products.
AtT20 cells were infected for
16 h with vv :7.5K-enk-derm at
an m.o.i . of 1 . Medium was
removed and the cells were
incubated for 1 h in serum-
free DMEM containing 0.07%
BSA, either in the presence
(N-0) or in the absence
(0-o) of 5mM 8-Br-cAMP
Media were collected, lyophi-
lized, dissolved in 0.1% TFA,
and applied to a C8 HPLC
column for reversed phase
chromatography . Fractions
were assayed by RIA for deca-
peptide (A) or met-enkephalin
(B) . The arrows indicate the
elution times of the standard
retention time (min)
￿
peptides.Figure 7 . Immunogold-EM .A-Cshow immunolabeled cryosections of AtT20 cells infected with vv:7.5K-enk-derm . Aand B show details
of the secretion granules at the periphery of the cells (P, plasma membrane ; V, vaccinia virus) . The large arrowheads indicate labeled
granules, while the small arrowheads indicate granules that have no labeling associated with them . InC a region of the Golgi complex
(G) is seen which has low but specific labeling over the stack (arrows) ; a labeled secretion granule is also evident (large arrowhead) .
Bars, 100 run .
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1131Table II. Quantitation of Cryo-section Labeling
Number of
micrographs
￿
Gold/Am' granules
vv:7 .5K-enk-derm
￿
12
￿
104.6 t 25 SEM
vv :7 .5K-derm
￿
12
￿
13.5 t 5 SEM
AtT-20 cells were infected with vv:7 .5K-derm or vv:7.5K-enk-derm for 16 h.
The cells were fixed, cryo-sectioned, and labeled with the antiserum anti-
[L-Ala-2]dermorphin 3A. Random micrographs were taken and the number of
gold particles per area of granule profile was estimated by point counting as
described previously (10).
ucts is a crucial step in this sorting process (1, 13, 34). Some
experimental evidence for this appealing theory has been
presented (9, 25) .
Dermal glands of amphibia may represent a special case
ofregulated secretion. In case ofXenopus laevis, these glands
are depleted by adrenergic stimulation. Their regeneration
within about3 wk proceeds via the accumulation ofsecretory
cells which subsequently fuse to form a syncytium filled with
ellipsoid granules (5, 7) . It is currently not known whether
this is also true for the dermal glands of Ph. sauvagei.
The results presented in this paper demonstrate that in
AtT20 cells, the precursor of the frog skin peptides dermor-
phin and deltorphin is not sorted into the regulated pathway
of secretion. As shown by pulse-chase experiments, proder-
morphin is largely retained in these cells and slowly
degraded. It is currently not known in which subcellular
compartment this degradation takes place. The fact that
leupeptin does partly inhibit the intracellular degradation of
pro-dermorphin indicates that lysosomal enzymes may be
involved in this process. About one third of unprocessed
prodermorphin is released constitutively. In a similar study,
it was recently shown that one of two somatostatin precur-
sors from anglerfish islets was also secreted constitutively in
transfected AtT20 cells (27).
Conversely, a hybrid protein containing the first 241
amino acids of prepro-enkephalin fused to the carboxy-
terminal part of prodermorphin is sorted and processed in
these cells. The secretion of the processing products deca-
peptide and met-enkephalin was stimulated by the addition
of 8-Br-cAMP Using immunogold-EM, this fusion protein,
but not pro-dermorphin, could in fact be detected in dense-
core granules. This indicates that the structural determinants
for entry into the regulated pathway may differ between am-
phibian and mammalian cells. In line with earlier findings
with chimeric polypeptides (18, 27, 29), these experiments
suggest that segregation into the regulated pathway of secre-
tion is an active process which depends on the presence of
certain "sorting domains'"
We were also interested to study the extent of processing
ofprodermorphin in mammalian cells. Processingof precur-
sors from organisms as diverse as yeast and mammals appear
to have common features. This is exemplified by the fact that
two yeast-processing enzymes, the KEX-2 endoprotease and
the KEX-1 carboxypeptidase, both function in mammalian
cells (32, 33). Using the proenkephalin-dermorphin fusion
protein, the extent of processing in AtT20 cells couldbe as-
sessed. Only the cleavage at pairs of basic amino acids and
their removal from newly exposed carboxyl ends was ob-
served . No further processing of the decapeptide occurred,
indicating that the enzyme that cleaves a dipeptide from the
The Journal of Cell Biology, Volume 114, 1991
carboxyl end and, in particular, the hypothetical enzyme
which converts the second amino acid of the end product
from the L- to the D-isomer are apparently not present in
AtT20 cells.
Our results show that besides common features present in
the secretory pathway of all animal cells, more specific and
restricted mechanisms operate in the sorting ofprecursors to
the regulated pathway and their subsequent processing.
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